Global NAFLD trial landscape shows GLP-1 drugs are the most frequently tested agents with downregulated liver receptor expression | Research

The takeaway

Analysis of 2,242 NAFLD clinical trials reveals GLP-1R agonists are the most frequently used agents, with GLP-1R expression significantly downregulated in NAFLD—especially in advanced NASH stages—based on molecular docking and transcriptomic data.

#1 tested drug class for NAFLD
GLP-1 drugs are the most frequently tested agents across 2,242 NAFLD trials, but GLP-1R downregulation in advanced disease raises efficacy questions

What the researchers found

2,242 trials analyzed. GLP-1RAs most frequently tested agents. US: 488 trials, China: 384. GLP-1R downregulated in NAFLD liver tissue. Further downregulation in NASH. Semaglutide binding confirmed by molecular docking.

Why it matters

Understanding that GLP-1R expression decreases as liver disease advances raises important questions about drug efficacy in severe NASH and may guide timing of treatment intervention.

How the study worked

Trialtrove database analysis (2,242 trials). Molecular docking of semaglutide-GLP-1R. Transcriptome analysis of NAFLD datasets (healthy vs NAFLD vs NASH). Geographic and phase distribution mapping.

What this study cannot tell us

Trial landscape analysis is descriptive. Transcriptomic analysis shows association not causation. GLP-1R downregulation mechanism unclear. Does not assess clinical trial outcomes.

How to read the evidence

Descriptive trial landscape analysis combined with bioinformatic analysis. Provides context rather than outcomes.

When this study was published

Published in 2025.

The bigger picture

The finding that the drug target (GLP-1R) is downregulated in advanced disease suggests GLP-1 drugs may work best early in NAFLD/NASH progression—supporting early intervention rather than waiting for advanced disease.

Questions still open

Does GLP-1R downregulation in advanced NASH reduce semaglutide efficacy?
Should NAFLD treatment with GLP-1 drugs begin at earlier stages?
Can GLP-1R expression be restored in NASH?

Common questions

Why are GLP-1 drugs the most tested for fatty liver?

GLP-1 drugs address multiple NAFLD drivers simultaneously: they reduce weight, improve insulin resistance, decrease inflammation, and have direct liver-protective effects. This makes them the most logical drug class for NAFLD, explaining why they lead in clinical trials.

Does it matter when you start GLP-1 treatment for fatty liver?

This study suggests it might. GLP-1 receptor expression decreases as fatty liver disease advances to NASH. This means the drug target becomes less available in sicker patients, potentially reducing effectiveness. Starting treatment earlier—before advanced disease—may be more effective.

Read the original research

The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.

International journal of surgery (London, England), 111(9), 6430-6434

View on PubMed ↗Publisher’s paper ↗

Citation

Sun, Jing; Shi, Run; Zhu, Xinrui; Liu, Yi; Shi, Wenjie; Zhao, Tianyu; Wang, Xuanbin; Zhou, Xiqiao. (2025). The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.. International journal of surgery (London, England), 111(9), 6430-6434. https://doi.org/10.1097/JS9.0000000000002654